The FDA Law Blog

SEPTEMBER 24, 2024

Livornese — FDA issued a Federal Register notice on September 13, 2024, seeking feedback on the Integrated Review format that the Center for Drug Evaluation and Research (CDER) began using as part of its New Drugs Regulatory Program (NDRP) modernization effort several years ago. 13, 2024). By Deborah L.

Documentation 57

Documentation FDA Packaging 57

Pharmaceutical Technology

APRIL 21, 2023

On 14 April, the FDA rejected Lilly’s biologic licence application (BLA) for their anti-interleukin (IL)-23, mirikizumab, which is in development for the treatment of ulcerative colitis (UC). The recent setback dents mirikizumab’s chances to be the first among the IL-23 inhibitors to launch in the US for UC.

FDA 52

FDA Packaging Labelling 52

STAT

JULY 11, 2024

This calls for celebration with a cup of stimulation, and we are opening a new package of blueberry muffin for the occasion. Novo said it does not expect to be able to fulfill the requests during 2024, delaying the program for several months at least. What is upon us right now, however, is our ever-growing to-do list. Sound familiar?

Packaging 91

Packaging FDA 91

European Pharmaceutical Review

AUGUST 26, 2024

The concentration of the formulation means the treatment can be administered ocularly via eye drops packaged in single-dose containers, according to SIFI. Akantior was granted Orphan Drug Designation from the US Food and Drug Administration (FDA) to treat acanthamoeba keratitis.

Packaging 69

Packaging Hospitals FDA 69

pharmaphorum

SEPTEMBER 15, 2022

The Massachusetts-based biotech said it a meeting with the FDA to discuss the programme has given it the confidence to press ahead with filing for approval of the RASP modulator in the US later this year. The post Aldeyra spies FDA filing ahead for dry eye drug reproxalap appeared first on. Image by StockSnap from Pixabay .

FDA 52

FDA Packaging 52

DiversifyRx

JULY 11, 2024

Small Dispensers and the 6/12/2024 FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. If the FDA or another regulator requests DSCSA transaction data, the DSCSA regulations give you up to 48 hours to respond. The original article can be found HERE.

Independent Pharmacies 52

Independent Pharmacies FDA Documentation CPhT 52

DiversifyRx

NOVEMBER 24, 2023

While DSCSA (the Drug Supply Chain Security Act) enforcement is postponed until November 2024, it is critical to move forward in becoming compliant sooner rather than later. This tracking involves the use of unique product identifiers, such as serial numbers and barcodes, on drug packaging to track their movement.

Independent Pharmacies 52

Independent Pharmacies Packaging Documentation FDA 52

The FDA Law Blog

JANUARY 11, 2024

Koblitz — Back in late September 2023 (and corrected in October), FDA issued its first interchangeable exclusivity determination pursuant to the Biologics Price Competition and Innovation Act (“BPCIA”). Notably, the purpose of the statute seemed to govern much of FDA’s interpretation.

FDA 57

FDA Packaging 57

The FDA Law Blog

MARCH 3, 2024

3558 ) on January 25, 2024. Effect on FDA approvals— In cases where a biological product or drug needs to change aspects of its manufacturing processes to avoid using a covered equipment or service, will it need to file supplements with FDA for the CMC update? House of Representatives ( H.B. 7085 ) and Senate ( S.B.

Packaging 101

Packaging FDA 101

Roots Analysis

AUGUST 1, 2024

Some of the GLP-1, namely Trulicity®, Mounjaro®, Zepbound®, Feisumei®, Rybelsus®, Ozempic®, Wegovy® were approved for the treatment of various target indication, by the US FDA and the EMA. per package in the US. Examples of some partnerships in this domain include: In May 2024, Sciwind Biosciences and HK inno.N

Insurance Coverage 52

Insurance Coverage Insurance Packaging Compounding 52

European Pharmaceutical Review

MARCH 28, 2024

FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. What is the main reason submission of the DVA qualification to FDA is significant for future clinical trials?

FDA 52

FDA Packaging Communication Insurance 52

The Checkup by Singlecare

APRIL 5, 2024

When the Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) in 2022 to treat Type 2 diabetes, some people hailed the GIP and GLP-1 medication as the next great antidiabetic drug. Samples often come in a package of four 2.5 And it’s not just hype. mg single-use pens, a one-month supply.

Insurance 59

Insurance Compounding Pharmacies Compounding Insurance Coverage 59

The Checkup by Singlecare

MARCH 7, 2024

It was approved by the Food and Drug Administration (FDA) in 2017 for treating Type 2 diabetes. In fact, many credible online platforms selling Ozempic only do so as part of a membership package, which actually increases your overall costs. Makhija explains, as the generic version is not FDA approved.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Packaging Insurance Coverage 52

The FDA Law Blog

SEPTEMBER 30, 2024

Despite the removal of some of the most controversial proposals, the final rule still contains a variety of significant changes, which become effective on November 19, 2024. The term “drug product information” is now defined to include NDC, drug name, units per package size (UPPS), drug category (S, I, or N), unit type (e.g.,

Vaccines 57

Vaccines Packaging FDA Documentation 57

European Pharmaceutical Review

APRIL 26, 2024

Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.

Packaging 98

Packaging Pharmaceutical Companies Pharmaceutical Companies FDA 98

Pharmaceutical Technology

JULY 29, 2022

This data has been shared with regulators, including the US Food and Drug Administration (FDA), and a request for US Emergency Use Authorisation (EUA) is planned. The EMA started a rolling review for this Omicron-adapted vaccine on 27 June and the FDA plans to review the vaccine for EUA. The expansion will be operational in 2024.

Vaccines 52

Vaccines Packaging Immunization FDA 52

The Checkup by Singlecare

MARCH 21, 2024

Its active ingredient, semaglutide, is FDA approved for weight loss under the brand name Wegovy , which has a dosing progression of 0.25 has said they expect the shortage to last at least until March 2024. The limits for 2024 are $22,590 for individuals and $30,660 for married couples. mg, 1 mg, 1.7 mg, and 2.4

Insurance Coverage 98

Insurance Coverage Insurance Dosage Mail-Order Pharmacies 98

PharmaShots

MARCH 1, 2023

osteoporosis in postmenopausal women and men with high fractures risk, treatment-induced bone loss The submission was based on the comprehensive analytical and clinical data package, incl. Under the co-development agreement, Similis Bio & Novel351k is expected to be valued at $100M incl. development milestones and royalties for ~10yrs.

FDA 40

FDA Packaging Labelling 40